



**MOVEMBER GLOBAL CANCER REAL WORLD EVIDENCE NETWORK
EXPRESSIONS OF INTEREST: GLOBAL COLLABORATIVE PROGRAM TO REDUCE DISEASE
PROGRESSION TO ADVANCED PROSTATE CANCER**

EOI QUESTIONS

APPLICANT INFORMATION

1. Personal Information
 - a. Title
 - b. First Name
 - c. Surname
2. Position (Primary Affiliation)
3. Institution (Primary Affiliation)
4. Email
5. Country
6. Qualification (e.g. MD, PhD)
7. Area(s) of Expertise (e.g. Medical oncologist, urologist, research scientists etc)

RESEARCH CAPABILITY & CAPACITY

8. Summary of your capability and capacity to contribute to the Global Collaborative Program in Disease Progression (maximum 500 words).

For this question, we are not soliciting proposals for projects. We are simply keen to understand what contributions you as an individual (or as an existing team) can contribute to a project of this nature. This information will inform the Program Advisory Committee with regards to decision-making around the appropriate representation for both the project and the Project Steering Committee.
9. Please provide details of your grants and key publications relevant to the research area within the past 10 years.
10. Please list research team member and their experience in relation to the research area.
11. In your opinion, what is the current unmet need in high-risk locally advanced prostate cancer and/or metastatic, hormone-sensitive prostate cancer (including de novo metastatic disease)?
12. In your opinion, what is the single most pressing piece of work to investigate the ways in which existing and/or emerging hormonal or systemic therapies can be selected and sequenced, to ensure the right treatment for the right patient at the right time?

EXPERIENCE IN PROSTATE CANCER RESEARCH

13. Please outline any current collaborations you have in prostate cancer.
14. A key focus of the program is to establish a multi-disciplinary collaboration as well as to leverage existing clinical data and patient samples collected through trials and real-world data. Please indicate your access to the following expertise / discipline:
 - Clinicians (Urology, Medical Oncology, Radiation Oncology etc)
 - Biostatisticians
 - Epidemiologists
 - Bioinformaticians
 - Pathologists



- Database Development / Management (e.g. image data, clinical data etc)
- Other (please specify)

15. Please provide details on your selections for Q14.

16. Please outline any other relevant resources you have access to in supporting the program objectives.

17. Please indicate your experience and capability in performing any of the following biomarker analysis:

- DNA (including methylation)
- RNA
- Protein
- Circulating Tumour Cells
- Circulating Tumour DNA
- Other (Please specify)

18. Please provide details on your selections for Q17.

19. Please provide details of experience with or access to new technologies (e.g. machine-learning / deep-learning for data analysis)

20. A key consideration for the new program is to identify opportunities to integrate with the Movember Global Cancer Real World Evidence Network in order to fast-track the delivery of research outcomes. Please provide details of any experience and capability in structured and standardised collection of real-world data.

21. Please provide details of any other relevant capabilities that will support the program objectives.

22. Movember is considering convening a face-to-face workshop in February 2022* with a selected Program Steering Committee in order to build and shape the detail of the project. The purpose of this meeting will be to hasten the collaborative, consensus-based approach used to build the project protocol. Details of the meeting will be shared with the team in due course after the EOI assessment process has been finalised. Please provide your general availability at this time and whether there will be any barrier to travel given the current situation with COVID-19?

*Potential workshop = After ASCO-GU (17-19 Feb, 2022) at San Francisco, USA

EXPRESSIONS OF INTEREST

To submit your EOI, please complete the form via the link below **by 5 January 2022**:

https://movember.qualtrics.com/jfe/form/SV_cUDqmHnvEsMaLrw

Movember will acknowledge receipt of EOI via email provided within two business days.

A list of FAQs will be posted on <https://movember.com/about/funding> with regular (weekly) updates.

Received EOIs will be evaluated for:

- Capability of research team – including track record of the team in establishing collaboration and/or partnerships
- Availability of resources – including existing pathway to ensure access to necessary data and/or resources required for the proposed research

TIMELINE

Milestones	Dates
EOI announcement	25 November 2021
EOI submission deadline	5 January 2022
EOI review by the Program Advisory Committee	10 January 2022 – 4 February 2022



Invitation to submit full project proposal from nominated working group/s	Week of 7 February 2022
Potential Project Steering Committee workshop(s)	Week of 14 February 2022 (at ASCO-GU / 17-19 February 2022, San Francisco, US)
Project proposal submission deadline	1 April 2022
Presentation of study proposal to Program Advisory Committee	(TBC) Week of 18 & 25 April 2022
Final project proposal submission (rebuttal)	(TBC) Week of 9 May 2022
Final project proposal review & assessment	(TBC) Week of 30 May 2022
Program outcome announcement	(TBC) Week of 20 June 2022

CONTACT

All enquires relating to this funding opportunity should be directed to Sarah Hsiao, Director (Biomedical Research & Impact) at biomed@movember.com.